The goal of this program is to inform the participant about the clinical and economic significance of drug interactions, review their potential mechanisms, present significant interactions related to antineoplastics, and provide resources for managing them.
Objectives
At the completion of this program, the participant will be able to:
1. Describe the scope and economic impact of preventable drug interactions.
2. Explain why oncology patients are at increased risk for drug interactions.
3. Define the pharmacokinetic, pharmacodynamic, and pharmaceutic principles underlying antineoplastic related drug–drug interactions.
4. List specific classes of antineoplastics involved in significant drug–drug interactions.
5. Identify multiple resources for obtaining drug interaction information.
JohnsonJ.A., BootmanJ.L.Drug-related morbidity and mortality: A cost-of-illness model. Arch Intern Med.1995; 155(18): 1949–56.
2.
ClassenD.C., PestotnikS.L., EvansR.S.Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA.1997; 277(4): 301–6.
3.
BatesD.W., SpellN., CullenD.J.The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA.1997; 277(4): 307–11.
4.
HardmanJ., LimbirdL.E., MolinoffP.B., eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics.9th ed.New York, NY: McGraw-Hill; 1996.
5.
FinleyR.S.Drug interactions in the oncology patient. Semin Oncol Nurs.1992; 8(2): 95–101.
6.
CiummoP.E., KatzN.L.Interactions and drug-metabolizing enzymes. Am Pharm.1995; 35(9): 41–53.
7.
CavalliF., HansenH.H., KayeS.B., eds. Textbook of Medical Oncology.2nd ed.London, England: Martin Dunitz Ltd; 2000.
8.
MichaletsE.L.Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy.1998; 18(1): 84–112.
9.
NelsonD.R., KoymansL., KamatakiT.P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics.1996; 6(1): 1–42.
10.
TatroD.S., ed. Drug Interaction Facts.St. Louis, MO: Facts and Comparisons; 2000 (updated quarterly).
11.
CreweH.K., EllisS.W., LennardM.S.Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol.1997; 53(2): 171–8.
12.
AnttilaM., LaaksoS., NylandenP.Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther.1995; 57(6): 628–35.
13.
Taxotere package insert.Collegeville, PA: Aventis Pharmaceuticals Products Inc.; January 2000.
14.
Physicians' Desk Reference.54th ed.Montvale, NJ: Medical Economics Company; 2000.
15.
MachoverD.A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer.1997; 80(7): 1179–87.
16.
TrisselL.A., ed. Handbook on Injectable Drugs.10th ed.Bethesda, MD: American Society of Health-System Pharmacists; 1998.
17.
CataniaP.N., ed. King Guide to Parenteral Admixtures.St. Louis, MO: King Guide Publications; 1996 (updated quarterly).
18.
ZuccheroF.J., HoganM.J., SchultzC.D., eds. Pocket Guide to Evaluations of Drug Interactions.3rd ed.Washington, DC: American Pharmaceutical Association; 1999.
19.
HanstenP.D., HornJr, eds. Hansten and Horn's Drug Interactions Analysis and Management.Vancouver, WA: Applied Therapeutics, Inc.; 1997 (quarterly updates).
ThyssA., MilanoG., KubarJ.Clinical and pharmacokinetic evidence of life-threatening interaction between methotrexate and ketoprofen. Lancet.1986; 1(8475): 256–8.
24.
FreniaM.L., LongK.S.Methotrexate and non-steroidal antiinflammatory drug interactions. Ann Pharmacother.1992; 26(2): 234–7.
25.
TracyT.S., WorsterT., BradleyJ.D.Methotrexate disposition following concomitant administration of ketoprofen, piroxicam, and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmac.1994; 37(5): 453–6.
26.
TracyT.S., KrohnK., JonesD.R.The effects of salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol.1992; 42(2): 121–5.
27.
MaicheA.G.Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet.1986; 1(8494): 1390.
28.
GreenstoneM., HartleyB., GabrielB.Acute nephrotic syndrome with reversible renal failure after phenylbutazone. Br Med J.1981; 282(6268): 950–1.
29.
DupuisL.L., KorenG., ShoreA.Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol.1990; 17(11): 1469–73.
30.
Soriatane package insert.Nutley, NJ: Roche Pharmaceuticals; August 1997.
31.
HaimN., KedarA., RobinsonE.Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum. Cancer Chemother Pharmacol.1984; 13(3): 223–5.
32.
CromW.R., TeresiM.E., MeyerW.H.The intrapatient effect of cisplatin therapy on the pharmacokinetics of high-dose methotrexate. Drug Intell Clin Pharm.1985; 19(6): 467.
CohenM.H., CreavenP.J., FossieckB.E.Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients. Cancer.1976; 38(4): 1556–9.
35.
RoncheraC.L., HernandezT., PerisJ.E.Pharmacokinetic interaction between high-dose methotrexate and amoxicillin. Ther Drug Monitor.1993; 15(5): 375–9.
36.
LillyM.B., OmuraG.A.Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid. Cancer Chemother Pharmacol.1985; 15(3): 220–2.
37.
FerrazziniG., KleinJ., SulhH.Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr.1990; 117(5): 823–6.
38.
ZimmS., CollinsJ.M., O'NeillD.Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther.1983; 34(6): 810–17.
39.
KennedyD.T., HayneyM.S., LakeK.D.Azathioprine and allopurinol: The price of an avoidable drug interaction. Ann Pharmacother.1996; 30(9): 951–4.
40.
BardakjiZ., JolivetJ., LangelierY.5-fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Cancer Chemother Pharmacol.1986; 18(2): 140–4.
41.
TobeS.W., SiuL.L., JamalS.A.Vinblastine and erythromycin: An unrecognized serious drug interaction. Cancer Chemother Pharmacol.1995; 35(3): 188–90.
42.
HoelzerK.L., HarrisonB.R., LuedkeS.W.Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin. Drug Intell Clin Pharm.1986; 20(4): 287–9.
43.
RaoS.X., RamaswamyG., LevinM.Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. Arch Intern Med.1985; 145(10): 1905–7.
44.
GilliesJ., HungK.A., FitzsimonsE.Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol.1998; 20(2): 123–4.
45.
BohmeA., GanserA., HoelzerD.Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol.1995; 71(6): 311–2.
46.
LumB.L., KaubischS., YahandaA.M.Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol.1992; 10(10): 1635–42.
47.
BisognoG., CowieF., BoddyA.High-dose cyclosporin with etoposide—toxicity and pharmacokinetic interaction in children with solid tumors. Br J Cancer.1998; 7(12): 2304–9.
48.
KomuneS., SnowJ.B.Potentiating effects of cisplatin and ethacrynic acid in ototoxicity. Arch Otolaryngol.1981; 107(10): 594–7.
49.
SelkerR.G., MooreP., LoDolceD.Bone-marrow depression with cimetidine plus carmustine. N Engl J Med.1978; 299(15): 834.
50.
VolkinR.L., ShadduckR.K., WinkelsteinA.Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine. Arch Intern Med.1982; 142(2): 243–5.
51.
BruléG., SchlumbergerJr, GriscelliC.N-isopropyl-a-(2-methylhydrazino)-p-toluamide, hydrochloride (NSC-77213) in treatment of solid tumors. Cancer Chemother Rep.1965; 44: 31–8.
52.
ToddI.D.H.Natulan in the management of late Hodgkin's disease, other lymphoreticular neoplasms, and malignant melanoma. Br Med J.1965; 1(5435): 628–31.
53.
VasiliouV., MalamasM., MarselosM.The mechanism of alcohol intolerance produced by various therapeutic agents. Acta Pharmacol Toxicol.1986; 58(5): 305–10.
54.
LienE.A., AnkerG., LonningP.E.Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res.1990; 50(18): 5851–7.
55.
LodwickR., McConkeyB., BrownA.M.Life threatening interaction between tamoxifen and warfarin. Br Med J.1987; 295(6606): 1141.
56.
RitchieL.D., GrantS.M.Tamoxifen-warfarin interaction: the Aberdeen hospital drug file. Br Med J.1989; 298(6682): 1253.
57.
TenniP., LalichD.L., ByrneJ.M.Life threatening interaction between tamoxifen and warfarin. Br Med J.1989; 298(6666): 93.
58.
WortsmanJ., SolerN.G.Mitotane. spirono-lactone antagonism in Cushing's syndrome. JAMA.1977; 238(23): 2527.
59.
Centers for Disease Control and Prevention.Use of vaccines and immune globulins in persons with altered immunocompetence: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR.1993; 42(No. RR-4): 1–18.
